NCT03236935View on ClinicalTrials.gov

Phase Ib of L-NMMA and Pembrolizumab

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 3, 2018

Primary Completion Date

October 31, 2021

Study Completion Date

December 28, 2025

Conditions
Non-Small Cell Lung CancerMalignant MelanomaHead and Neck Squamous Cell CarcinomaClassical Hodgkin LymphomaUrothelial Carcinoma BladderDNA Repair-Deficiency Disorders
Interventions
DRUG

L-NMMA

pan-nitric oxide synthase inhibitor

DRUG

Pembrolizumab

PD-1 inhibitor

Trial Locations (1)

77030

Houston Methodist Cancer Center, Houston

All Listed Sponsors
lead

The Methodist Hospital Research Institute

OTHER